»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 1gCp/m2r7
;~xkT'
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 H-0deJ[>
'B6D&xn'%&
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© |)GE7y0Q
1.Antigen presenting cell£¨APC£© %o*afd
2.Activation induced cell death£¨AICD£© ]$KH78MTW
3.Chemokine kw?RUt0-V
4.Major histocompatibility complex£¨MHC£© #WfJz}P,!
5.immunotolerance d4A}BTs1
zBqr15
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© BKV vu}V(o
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ X @r5^A[9
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà ^c.b@BE
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ D~8f6Ko"m
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ IKAF%0[R|j
5.±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌصã o$Hc5W([Z
ou96
P<B
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© 574b]
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ 0H;dA1
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ d p_J*8
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ qdUlT*fw
9lOUE
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ gY;N>Yq,C
qfN<w&P
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 I8`.eqV
VJuPC
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ r|rV1<d
1.Antigenic determinant :tR%y"
2.IgSF :sM|~gT
3.MBL;¾¶ 7Zr jU{
4.chemokine lm-ubzJN
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ ;#f_e;
6.TCR-CD3¸´ºÏÎï I%{U~
7.FADD£¨Fas-associated protein with death domain£© 'KyT]OObS
8.AIDS ^k u~m5v
9.Tumor rejection antigen z36ny o
10.AICD TvM{ QGN
q_HD`tW
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ "fz-h
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© o{>hOs
&
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ VVCCPK^<
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ '[Nu;(>a
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì zse!t
w&f29#i;b
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ kl2]#G(
<&W3\/xx
tDIzn`$z
רҵ¿Î ÃâÒßѧ sM~C
P zMa
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 1Rl`}7Km
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell @JN%P}4)
5. Fc¦Å receptor 6. Cytokine dqd Qt_
¶þ¡¢ ÎÊ´ðÌâ rr9HC]63
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØɱÉË°Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 kC LeHH|K
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ <<n8 P5pXt
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁÜ°ÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ EcwHO
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâЩÌصãµÄÉúÎïѧÒâÒ壿 a.w,@!7
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠ1
4(?mM3
=PO/Q|-v?
yfP&Q<|
N} Q,
QRt(?96
6p1TI1(
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ @h^5*M
<_42h|-
})&0e:6
רҵ¿Î ÃâÒßѧ m=%W <8[V
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê t'[vN~I'
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen O\G%rp L$w
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin CR,
Y%0vQ
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test ,[cWG)-
9. Hybridoma technic 10.Mitogen %/S BJ
11.Dentritic cell 12.Immunoproliferation @?gH3Y_
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ cl)MI,/>
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨Äļ¸¸öÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ #uey1I@"9
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ* z{D}L-&
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ IP{Cj=
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ u#
%7>=
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ jp[QA\
c~$ipX
lXB_
HDY
<`MHra8
\&e+f#!u
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 1noFXz
eU3
:mg#&MZj<
T-<^mX[}
רҵ¿Î ÃâÒßѧ L`"cu.l
Ò»¡¢ Ãû´Ê½âÊÍ v $pARt
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï dC.uK^FuJ
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà T /]ayc:
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ Z?v9ub~%
¶þ¡¢ ÎÊ´ðÌâ ?]P&3UU>0z
1¡¢ TÁÜ°Íϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ qrt+{5/t
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁÜ°Íϸ°ûºÍЧӦÎïÖÊ¡£ m6IZGl7%
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆ乲ͬÌص㼰ÓëÁÙ´²µÄ¹Øϵ¡£ $@K+yOq+u
4¡¢ ºÎνÁÜ°Íϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ KNK0w 5
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØϵͳ£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ `qfVgT=2
-iJ[9O
y XS/3_A{
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ Hq%`DWus\
jMw;`yh
L8ZCGW\Rr
רҵ¿Î ÃâÒßѧ *XNvb ^<
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê J@R+t6$3O
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR G=b`w;oL:
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA !CsoTW9C:
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM D|+H!f{k
¶þ¡¢ ÎÊ´ðÌâ >\@6i
s
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌص㡣 Y RA[qc
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ ^pg5o)M
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖƵÄÒìͬµã¡£ 9V
P|a-
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆ书ÄÜ¡£ Q2Q`g`* O:
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ 73]%^kx=
)W
c#?K
jo"[$%0`
9@:&